A Phase 3 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 77 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 15th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2022.
This study's enrollment of 305 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 100th largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 121 in phase 3, and was the 290th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller medications.
This is a multicentre, single-arm, phase 3b study designed to evaluate efficacy and safety of reducing daily oral corticosteroid use after initiation of 210 mg dose of Tezepelumab administered subcutaneously in patients with severe asthma receiving high-dose inhaled corticosteroid plus long-acting β2 agonist and oral corticosteroids with or without additional asthma controller medications.
Main inclusion criteria:
Other inclusion criteria per protocol apply.
Main exclusion criteria:
Other exclusion criteria per protocol apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection
Biological: Tezepelumab
Tezepelumab subcutaneous injection
Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52
The proportion (expressed as a percentage) of participants who discontinued OCS without loss of asthma control is presented. Loss of asthma control was defined as asthma worsening or exacerbation. Asthma worsening was defined by an increase of Asthma Control Questionnaire 6 (ACQ-6) score ≥0.5 from baseline. Asthma exacerbation was defined by worsening of asthma symptoms that led to temporary bolus/burst of systemic corticosteroids (SCS; or a temporary increase in stable OCS background dose) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids being considered equivalent to a 3-day bolus/burst of SCS), and/or an emergency room (ER) or urgent care visit requiring SCS, and/or inpatient hospitalisation, both due to asthma.
Time frame: Week 28 and Week 52
Proportion of the Participants Who Reduced Daily Prescribed Maintenance OCS Dose to ≤5 mg/Day Without Loss of Asthma Control at Week 28 and Week 52
The proportion (expressed as a percentage) of the participants who reduced daily prescribed maintenance OCS dose to ≤5 mg/day without loss of asthma control at Week 28 and Week 52 is presented.
Time frame: Week 28 and Week 52
Annual Asthma Exacerbation Rate (AAER) Over Week 28 and Over Week 52
The AAER over Week 28 and over Week 52 is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
Time frame: Week 28 and Week 52
Rate of Asthma Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks
The AAER for exacerbations associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
Time frame: Week 28 and Week 52
Rate of Asthma Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks
The AAER for exacerbations associated with hospitalisation over 28 weeks and over 52 weeks are presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
Time frame: Week 28 and Week 52
Proportion of the Participants Who Did Not Experience an Exacerbation Over 28 Weeks and Over 52 Weeks
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation over 28 weeks and over 52 weeks is presented.
Time frame: Week 28 and Week 52
Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation or ER Visit Over 28 Weeks and Over 52 Weeks
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented.
Time frame: Week 28 and Week 52
Proportion of the Participants Who Did Not Experience an Exacerbation Associated With Hospitalisation Over 28 Weeks and Over 52 Weeks
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation over 28 weeks and over 52 weeks is presented.
Time frame: Week 28 and Week 52
Proportion of the Participants With ≥50% Reduction From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
The proportion (expressed as a percentage) of participants with ≥50% reduction from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of investigational product (IP). The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
Time frame: Week 28 and Week 52
Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 and Week 52
The categorised percent reduction from baseline in the daily maintenance OCS dose (categories: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, no change or any increase) at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
Time frame: Week 28 and Week 52
Absolute Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
The absolute change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
Time frame: Week 28 and Week 52
Percent Change From Baseline in Daily Maintenance OCS Dose at Week 28 and Week 52
The percent change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
Time frame: Week 28 and Week 52
Change From Baseline in Post-bronchodilator FEV1 at Week 28 and Week 52
The change from baseline in post-bronchodilator FEV1 at Week 28 and Week 52 is presented. Baseline was defined as the last measurement at or prior first dose of IP. FEV1 = forced expiratory volume in 1 second
Time frame: Week 28 and Week 52
Change From Baseline in ACQ-6 at Week 28 and Week 52
The Asthma Control Questionnaire 6 (ACQ-6) is a 6-item questionnaire which includes the following questions: 1) Awakening at night by symptoms, 2) Limitations of normal daily activities, 3) Waking in the morning with symptoms, 4) Dyspnoea, 5) Wheeze, and 6) Daily rescue medication. Questions were scored from 0 (totally controlled) to 6 (severely uncontrolled) and the ACQ-6 score was computed as the unweighted mean of the responses to the 6 questions. Higher scores indicate poorer outcomes. The change from baseline in ACQ-6 at Week 28 and Week 52 is presented.
Time frame: Week 28 and Week 52
Change From Baseline in Standardised AQLQ(s)+12 Total Score at Week 28 and Week 52
The Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ\[S\]+12) is a questionnaire that measures the health-related quality of life experienced by asthma participants. Questions were scored from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. Higher scores indicate better outcomes. The change from baseline in standardised AQLQ(S)+12 total score at Week 28 and Week 52 is presented.
Time frame: Week 28 and Week 52
Change From Baseline in SGRQ Total Score at Week 28 and Week 52
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item instrument developed to measure the health status of participants with airway obstruction diseases. The total score indicates the impact of disease on overall health status. The total score ranges for the SGRQ are 0-100, with higher scores indicating worse health status. The change from baseline in SGRQ total score at Week 28 and Week 52 is presented.
Time frame: Week 28 and Week 52
A total of 305 participants were enrolled from 68 study sites across 11 countries, including sites in Argentina, Belgium, Bulgaria, France, Germany, Latvia, Mexico, Poland, Spain, UK, and USA.
| Milestone | Tezepelumab |
|---|---|
| Started | 298 |
| Completed | 273 |
| Not completed | 25 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 2 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawn from study due to investigator's decision | 1 |
| Withdrew: Withdrawn from study due to participant's decision to withdraw | 1 |
| Withdrew: Withdrawn from study due to severe non-compliance with the protocol | 1 |
| Withdrew: Withdrawn from study due to subject decision | 1 |
| Withdrew: Withdrawn due to participant's decision not to continue for personal and family reasons | 1 |
| Withdrew: Withdrawn from study due to the participant stopped visit; agreed to a telephone contact at week 52 | 1 |
| Withdrew: Withdrawn from study due to randomization into closed cohort by mistake | 1 |
| Withdrew: Withdrawal by subject | 11 |
The proportion (expressed as a percentage) of participants who discontinued OCS without loss of asthma control is presented. Loss of asthma control was defined as asthma worsening or exacerbation. Asthma worsening was defined by an increase of Asthma Control Questionnaire 6 (ACQ-6) score ≥0.5 from baseline. Asthma exacerbation was defined by worsening of asthma symptoms that led to temporary bolus/burst of systemic corticosteroids (SCS; or a temporary increase in stable OCS background dose) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids being considered equivalent to a 3-day bolus/burst of SCS), and/or an emergency room (ER) or urgent care visit requiring SCS, and/or inpatient hospitalisation, both due to asthma.
| Percentage of participants | Tezepelumab |
|---|---|
| Week 28 | 32.2 (26.9 to 37.8) |
| Week 52 | 50.3 (44.5 to 56.2) |
The proportion (expressed as a percentage) of the participants who reduced daily prescribed maintenance OCS dose to ≤5 mg/day without loss of asthma control at Week 28 and Week 52 is presented.
| Percentage of participants | Tezepelumab |
|---|---|
| Week 28 | 88.9 (84.8 to 92.3) |
| Week 52 | 89.9 (85.9 to 93.1) |
The AAER over Week 28 and over Week 52 is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
| exacerbations/year | Tezepelumab |
|---|---|
| Week 28 | 0.66 |
| Week 52 | 0.57 |
The AAER for exacerbations associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
| exacerbations/year | Tezepelumab |
|---|---|
| Week 28 | 0.13 |
| Week 52 | 0.11 |
The AAER for exacerbations associated with hospitalisation over 28 weeks and over 52 weeks are presented. The AAER was calculated as the total number of asthma exacerbations over the period (Week 28/52) divided by the total time at risk for the period (Week 28 or Week 52).
| exacerbations/year | Tezepelumab |
|---|---|
| Week 28 | 0.06 |
| Week 52 | 0.05 |
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation over 28 weeks and over 52 weeks is presented.
| Percentage of participants | Tezepelumab |
|---|---|
| Week 28 | 76.0 (70.68 to 80.85) |
| Week 52 | 66.9 (61.01 to 72.44) |
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation or ER visit over 28 weeks and over 52 weeks is presented.
| Percentage of participants | Tezepelumab |
|---|---|
| Week 28 | 95.5 (92.40 to 97.57) |
| Week 52 | 92.7 (88.99 to 95.50) |
The proportion (expressed as a percentage) of participants who completed 28 or 52 weeks of treatment and did not experience an exacerbation associated with hospitalisation over 28 weeks and over 52 weeks is presented.
| Percentage | Tezepelumab |
|---|---|
| Week 28 | 97.9 (95.52 to 99.23) |
| Week 52 | 96.0 (92.96 to 97.99) |
The proportion (expressed as a percentage) of participants with ≥50% reduction from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of investigational product (IP). The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
| Percentage of participants | Tezepelumab |
|---|---|
| Week 28 | 76.8 (71.6 to 81.5) |
| Week 52 | 81.9 (77.0 to 86.1) |
The categorised percent reduction from baseline in the daily maintenance OCS dose (categories: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, no change or any increase) at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
| Percentage of participants | Tezepelumab (Week 28) |
|---|---|
| Week 28: ≥90% to ≤100% reduction | 35.2 (29.8 to 41.0) |
| Week 28: ≥75% to <90% reduction | 14.1 (10.4 to 18.6) |
| Week 28: ≥50% to <75% reduction | 27.5 (22.5 to 33.0) |
| Week 28: >0% to <50% reduction | 8.1 (5.2 to 11.7) |
| Week 28: No change or any increase | 15.1 (11.2 to 19.7) |
| Week 52: ≥90% to ≤100% reduction | 52.0 (46.2 to 57.8) |
| Week 52: ≥75% to <90% reduction | 9.1 (6.1 to 12.9) |
| Week 52: ≥50% to <75% reduction | 20.8 (16.3 to 25.9) |
| Week 52: >0% to <50% reduction | 4.0 (2.1 to 6.9) |
| Week 52: No change or any increase | 14.1 (10.4 to 18.6) |
The absolute change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
| mg | Tezepelumab |
|---|---|
| Week 28 | -6.951 ± 5.596 |
| Week 52 | -7.704 ± 6.294 |
The percent change from baseline in daily maintenance OCS dose at Week 28 and Week 52 is presented. The baseline OCS dose is the prescribed OCS dose prior to first dose of IP. The final daily OCS dose was defined as the last dose reported by participants with asthma stability verified (no change in OCS dose for at least 2 consecutive weeks).
| Percentage change | Tezepelumab |
|---|---|
| Week 28 | -61.919 ± 41.773 |
| Week 52 | -69.844 ± 43.666 |
The change from baseline in post-bronchodilator FEV1 at Week 28 and Week 52 is presented. Baseline was defined as the last measurement at or prior first dose of IP. FEV1 = forced expiratory volume in 1 second
| liter (L) | Tezepelumab |
|---|---|
| Week 28 | 0.0885 ± 0.3405 |
| Week 52 | 0.0737 ± 0.3559 |
The Asthma Control Questionnaire 6 (ACQ-6) is a 6-item questionnaire which includes the following questions: 1) Awakening at night by symptoms, 2) Limitations of normal daily activities, 3) Waking in the morning with symptoms, 4) Dyspnoea, 5) Wheeze, and 6) Daily rescue medication. Questions were scored from 0 (totally controlled) to 6 (severely uncontrolled) and the ACQ-6 score was computed as the unweighted mean of the responses to the 6 questions. Higher scores indicate poorer outcomes. The change from baseline in ACQ-6 at Week 28 and Week 52 is presented.
| Score on a scale | Tezepelumab |
|---|---|
| Week 28 | -1.12 ± 1.00 |
| Week 52 | -1.20 ± 1.09 |
The Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ\[S\]+12) is a questionnaire that measures the health-related quality of life experienced by asthma participants. Questions were scored from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. Higher scores indicate better outcomes. The change from baseline in standardised AQLQ(S)+12 total score at Week 28 and Week 52 is presented.
| Score on a scale | Tezepelumab |
|---|---|
| Week 28 | 1.1455 ± 1.0419 |
| Week 52 | 1.1932 ± 1.1551 |
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item instrument developed to measure the health status of participants with airway obstruction diseases. The total score indicates the impact of disease on overall health status. The total score ranges for the SGRQ are 0-100, with higher scores indicating worse health status. The change from baseline in SGRQ total score at Week 28 and Week 52 is presented.
| score | Tezepelumab |
|---|---|
| Week 28 | -16.2919 ± 18.1489 |
| Week 52 | -16.6593 ± 18.7749 |
Collected over From the date of first dose of IP until study completion or withdrawal date, up to 64 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab | 2/298 (0.7%) | 28/298 (9.4%) | 4/298 (1.3%) |
| Event | Tezepelumab |
|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 13/298 |
| PneumoniaInfections and infestations | 3/298 |
| Angina pectorisCardiac disorders | 2/298 |
| Atrial fibrillationCardiac disorders | 2/298 |
| Adrenocortical insufficiency acuteEndocrine disorders | 1/298 |
| DysphagiaGastrointestinal disorders | 1/298 |
| GastritisGastrointestinal disorders | 1/298 |
| Pancreatitis acuteGastrointestinal disorders | 1/298 |
| VomitingGastrointestinal disorders | 1/298 |
| Bile duct stoneHepatobiliary disorders | 1/298 |
| Event | Tezepelumab |
|---|---|
| Adrenal insufficiencyEndocrine disorders | 1/298 |
| InsomniaPsychiatric disorders | 1/298 |
| Atrial fibrillationCardiac disorders | 1/298 |
| TinnitusEar and labyrinth disorders | 1/298 |
Full Analysis Set: included all enrolled participants who received at least one dose of tezepelumab, irrespective of their protocol adherence and continued participation in the study.
| Age, Continuous(Years) | Tezepelumab |
|---|---|
| Mean | 54.4 ± 12.0 |
| Age, Customized(Participants) | Tezepelumab |
|---|---|
| >=18 to <65 years | 231 |
| >=65 years | 67 |
| Sex: Female, Male(Participants) | Tezepelumab |
|---|---|
| Female | 206 |
| Male | 92 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab |
|---|---|
| Hispanic or Latino | 123 |
| Not Hispanic or Latino | 157 |
| Missing | 18 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab |
|---|---|
| Black or African American | 2 |
| American Indian or Alaska Native | 5 |
| White | 258 |
| Other | 15 |
| Not reported | 18 |
| Region of Enrollment(Participants) | Tezepelumab |
|---|---|
| Argentina | 80 |
| Belgium | 13 |
| Bulgaria | 36 |
| France | 18 |
| Germany | 22 |
| Latvia | 16 |
| Mexico | 41 |
| Poland | 40 |
| Spain | 8 |
| United States | 12 |
| United Kingdom | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of the timelines, please rerefer to the disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from May 2022 to primary completion in Sep 2024, 27 months.
Results were first posted in Dec 2025, 1 year 3 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab